mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2019-2-22-24mrj-906Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL GUIDELINESОбзор рекомендаций Европейской антиревматической лиги (EULAR), рассмотренных в 2018 г.Review of the European League Against Rheumatism (EULAR) guidelines considered in 2018БекетоваТ. В.BeketovaT. V.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoye Shosse, Moscow 115522

tvbek@rambler.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2019130520191322224Copyright © Бекетова Т.В., 20192019Бекетова Т.В.Beketova T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/906

Представлен обзор новых рекомендаций Европейской антиревматической лиги (European League Against Rheumatism, EULAR), затрагивающих широкий круг вопросов ревматологии, которые обсуждались на конгрессе EULAR в 2018 г.

The paper reviews the new European League Against Rheumatism (EULAR) guidelines covering a wide range of rheumatology issues discussed at the 2018 EULAR Congress.

Европейская лига против ревматизмарекомендации 2018 г.European League Against Rheumatismthe 2018 guidelinesReferencesRetamozo S. SP0159 EULAR recommendations for the management of Sjö gren's syndrome. Ann Rheum Dis. 2018 Jun;77 (Suppl 2):42.Retamozo S. SP0159 EULAR recommendations for the management of Sjö gren's syndrome. Ann Rheum Dis. 2018 Jun;77 (Suppl 2):42.Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of Rituximab treatment in primary Sjö gren's syndrome. A Randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Apr;62(4):960-8. doi: 10.1002/art.27314.Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of Rituximab treatment in primary Sjö gren's syndrome. A Randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Apr;62(4):960-8. doi: 10.1002/art.27314.Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjö gren's Syndrome. Arthritis Rheum. 2017 Jul;69(7):1440-1450. doi: 10.1002/art. 40093.Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjö gren's Syndrome. Arthritis Rheum. 2017 Jul;69(7):1440-1450. doi: 10.1002/art. 40093.Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behсet's syndrome. Ann Rheum Dis. 2018 Jun;77(6): 808-818. doi: 10.1136/annrheumdis-2018- 213225. Epub 2018 Apr 6.Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behсet's syndrome. Ann Rheum Dis. 2018 Jun;77(6): 808-818. doi: 10.1136/annrheumdis-2018- 213225. Epub 2018 Apr 6.Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behсet disease. Ann Rheum Dis. 2008 Dec;67(12):1656-62. doi: 10.1136/ard.2007.080432. Epub 2008 Jan 31.Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behсet disease. Ann Rheum Dis. 2008 Dec;67(12):1656-62. doi: 10.1136/ard.2007.080432. Epub 2008 Jan 31.Elkayam O. SP0158 Update of eular recommendations for vaccination of patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2018 Jun;77 (Suppl 2):41.Elkayam O. SP0158 Update of eular recommendations for vaccination of patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2018 Jun;77 (Suppl 2):41.Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011 Mar;70(3):414-22. doi: 10.1136/ard.2010.137216. Epub 2010 Dec 3.Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011 Mar;70(3):414-22. doi: 10.1136/ard.2010.137216. Epub 2010 Dec 3.Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007 Dec;66(12):1560-7. Epub 2007 Jul 27.Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007 Dec;66(12):1560-7. Epub 2007 Jul 27.Van der Goes MC, Jacobs JW, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2010 Jun;69(6):1015-21. doi: 10.1136/ard.2009.114579.Van der Goes MC, Jacobs JW, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2010 Jun;69(6):1015-21. doi: 10.1136/ard.2009.114579.Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensusbased recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013 Dec;72(12):1905-13. doi: 10.1136/annrheumdis-2013-203249. Epub 2013 Jul 19.Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensusbased recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013 Dec;72(12):1905-13. doi: 10.1136/annrheumdis-2013-203249. Epub 2013 Jul 19.Buttgereit F. SP0160 2018 EULAR recommendations for the use of glucocorticoid therapy. Ann Rheum Dis. 2018 Jun;77(Suppl 2):42.Buttgereit F. SP0160 2018 EULAR recommendations for the use of glucocorticoid therapy. Ann Rheum Dis. 2018 Jun;77(Suppl 2):42.Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007 Mar; 66(3):377-88. Epub 2006 Oct 17.Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007 Mar; 66(3):377-88. Epub 2006 Oct 17.Kloppenburg M, Kroon FP, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019 Jan; 78(1):16-24. doi: 10.1136/annrheumdis2018-213826. Epub 2018 Aug 28.Kloppenburg M, Kroon FP, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019 Jan; 78(1):16-24. doi: 10.1136/annrheumdis2018-213826. Epub 2018 Aug 28.Lems WF, Dreinhö fer KE, Bischoff-Ferrari H, et al. EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. Ann Rheum Dis. 2017 May;76(5): 802-810. doi: 10.1136/annrheumdis-2016- 210289. Epub 2016 Dec 22.Lems WF, Dreinhö fer KE, Bischoff-Ferrari H, et al. EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. Ann Rheum Dis. 2017 May;76(5): 802-810. doi: 10.1136/annrheumdis-2016- 210289. Epub 2016 Dec 22.

The authors declare that there are no conflicts of interest present.